Publication Date:
2015
abstract:
The fibroblast growth factor (FGF)/FGF receptor (FGFR) system plays a
crucial role in cancer by affecting tumor growth, angiogenesis, drug
resistance, and escape from anti-angiogenic anti-vascular endothelial
growth factor therapy. The soluble pattern recognition receptor
long-pentraxin 3 (PTX3) acts as a multi-FGF antagonist. Here we
demonstrate that human PTX3 overexpression in transgenic mice driven by
the Tie2 promoter inhibits tumor growth, angiogenesis, and metastasis in
heterotopic, orthotopic, and autochthonous FGF-dependent tumor models.
Using pharmacophore modeling of the interaction of a minimal
PTX3-derived FGF-binding pentapeptide with FGF2, we identified a
small-molecule chemical (NSC12) that acts as an extracellular FGF trap
with significant implications in cancer therapy.
crucial role in cancer by affecting tumor growth, angiogenesis, drug
resistance, and escape from anti-angiogenic anti-vascular endothelial
growth factor therapy. The soluble pattern recognition receptor
long-pentraxin 3 (PTX3) acts as a multi-FGF antagonist. Here we
demonstrate that human PTX3 overexpression in transgenic mice driven by
the Tie2 promoter inhibits tumor growth, angiogenesis, and metastasis in
heterotopic, orthotopic, and autochthonous FGF-dependent tumor models.
Using pharmacophore modeling of the interaction of a minimal
PTX3-derived FGF-binding pentapeptide with FGF2, we identified a
small-molecule chemical (NSC12) that acts as an extracellular FGF trap
with significant implications in cancer therapy.
Iris type:
1.1 Articolo in rivista
List of contributors:
Ronca, Roberto; Giacomini, Arianna; Di Salle, Emanuele; Coltrini, Daniela; Pagano, Katiuscia; Ragona, Laura; Matarazzo, Sara; Rezzola, Sara; Maiolo, Daniele; Torella, Rubben; Moroni, Elisabetta; Mazzieri, Roberta; Escobar, Giulia; Mor, Marco; Colombo, Giorgio; Presta, Marco
Published in: